The miRNA-mediated regulation of the TGF-β pathway and ECM synthesis positions SGLT2 inhibitors as promising therapeutic agents in the management of cardiovascular fibrosis associated with diabetes and heart failure. The gene discussed is SLC5A2; the disease is heart failure.